IN8bio, Inc.
IN8bio, Inc.（INAB）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · INAB · 截至 2025年9月30日
股东结构概览
20
机构持有人数
▲ 8 vs Q2
$2.13M
机构持仓总市值
▲ $297,562 vs Q2
4.64M
总流通股
freeFloat 71.13%
980,421
13F 申报持股数
▲ 104,940 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
INAB 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BIOS CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 286.7K | 6.32% | 6.32% | $622.06M | Nov 12, 2025 | — held |
FRANKLIN RESOURCES INC biological products, (no diagnostic substances) | 189.9K | 4.18% | 4.18% | $412.07M | Nov 13, 2025 | — held |
STONEPINE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 159.4K | 3.51% | 3.51% | $345.94M | Nov 13, 2025 | ▲ 77.0K |
ALYESKA INVESTMENT GROUP, L.P. biological products, (no diagnostic substances) | 82.5K | 1.82% | 1.82% | $178.99M | Nov 17, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 59.4K | 1.31% | 1.31% | $128.94M | Nov 7, 2025 | ▼ 679 |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 49.5K | 1.09% | 1.09% | $107.31M | Nov 14, 2025 | NEW |
TWO SIGMA ADVISERS, LP biological products, (no diagnostic substances) | 45.8K | 1.01% | 1.01% | $99.28M | Nov 14, 2025 | NEW |
JANE STREET GROUP, LLC biological products, (no diagnostic substances) | 26.2K | 57.70% | 57.70% | $56.81M | Nov 14, 2025 | NEW |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 24.7K | 54.49% | 54.49% | $53.66M | Nov 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 19.3K | 42.52% | 42.52% | $41.87M | Nov 12, 2025 | ▲ 472 |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
4
增持
+79.0K 股9
新建仓
首次建仓3
减持
−1.3K 股1
清仓
完全退出净股数变化（前50家）
+77.7K
+79.0K / −1.3K
净新增持仓人
+9
新建 9 个 / 退出 1 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
INAB 内幕交易记录
数据来源：SEC Form 4
9
买入笔数
1
卖出笔数
9.00
买卖比
$1M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
FAIRBAIRN EMILY director | May 27, 2026 | Gift | 724,637 | — | — | 0 | Form 4 ↗ |
Ho William Tai-Wei CEO | May 9, 2026 | Award | 154,500 | $1.58 | $244.1K | 154.5K | Form 4 ↗ |
Greenwood Luba director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
Lamb Lawrence EVP and CSO | May 9, 2026 | Award | 54,000 | $1.58 | $85.3K | 54.0K | Form 4 ↗ |
FAIRBAIRN EMILY director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
McCall Patrick CHIEF FINANCIAL OFFICER | May 9, 2026 | Award | 56,250 | $1.58 | $88.9K | 56.3K | Form 4 ↗ |
Rochlin Kate President and COO | May 9, 2026 | Award | 60,000 | $1.58 | $94.8K | 60.0K | Form 4 ↗ |
Epperly Corinne director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
Brandt Peter C. director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
Graff Jeremy R. director | May 9, 2026 | Award | 22,000 | $1.58 | $34.8K | 22.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
IN8bio, Inc.（INAB）主要由机构投资者持有，机构持股比例约为 21.1%。公司内部人员持股约 28.87%，散户及公众持股约占剩余的 49.98%。
IN8bio, Inc. 最大机构股东为 BIOS CAPITAL MANAGEMENT, LP，截至 September 30, 2025 持有约 286,664 股，占总流通股的 6.32%。
目前共有 20 家机构持有 INAB 股票，合计持仓市值约 $2,127,322，数据来源为最新 SEC 13F 申报。
常见问题
INAB ownershipIN8bio, Inc.（INAB）主要由机构投资者持有，机构持股约 21.1%。最大股东为 BIOS CAPITAL MANAGEMENT, LP，持股比例 6.32%。内部人员持股约 28.87%。数据来源 SEC Form 13F，截至 September 30, 2025。